Global Market Access and Reimbursement Playbook

Chapter 1. Introduction and How to Use This Playbook

1.1 Purpose and Scope of the Playbook
1.2 Who This Playbook Is For (and Who It Is Not For)
1.3 Typical Market Access Project Archetypes
1.4 How to Navigate the Chapters and Tools
1.5 Using the Playbook Alongside Internal SOPs and Governance

Chapter 2. Defining Market Access and Reimbursement

2.1 What Is Market Access? A Working Definition
2.2 How Market Access Differs from Pricing, HEOR, and Commercial
2.3 Key Stakeholders: Regulators, HTA Bodies, Payors, Providers, Patients
2.4 The End-to-End Market Access Journey Across the Asset Lifecycle
2.5 Success Metrics for Market Access and Reimbursement

Chapter 3. Global Healthcare Financing and Payor Landscapes

3.1 Major Health System Archetypes (Tax-Funded, SHI, Private, Mixed)
3.2 Types of Payors: Public, Private, Integrated Delivery Systems, PBMs
3.3 Global Trends Reshaping Market Access (Cost Containment, Outcomes, Equity)
3.4 Access Barriers: Regulatory, Financial, Structural, and Behavioral
3.5 Implications of System Design for Market Access Strategy

Chapter 4. Core Frameworks for Market Access Strategy

4.1 The Value-Access-Pricing (VAP) Triangle
4.2 “Three Lenses” Framework: Clinical, Economic, and Societal Value
4.3 Segmentation of Payors, Providers, and Patient Pathways
4.4 Access Archetypes by Asset Type (Primary Care, Specialty, Rare, Cell & Gene)
4.5 From Global Value Strategy to Local Access Tactics

Chapter 5. Regulatory and HTA Bodies in Major Markets

5.1 United States: FDA, CMS, Commercial Insurers, and PBMs
5.2 Europe: EMA and Key HTA/Price Bodies (e.g., NICE, HAS, G-BA, AIFA, etc.)
5.3 Asia-Pacific: PMDA (Japan), NMPA/NRDL (China), and Other Key Agencies
5.4 Latin America and Middle East: ANVISA, COFEPRIS, GCC Bodies, and Others
5.5 Cross-Market Patterns: Roles, Mandates, and Decision Criteria

Chapter 6. Establishing Market Access and Reimbursement in Major Markets

6.1 United States: Coverage, Coding, and Payment Pathways
6.2 Europe: Centralized Approval, National HTA, and Local Implementation
6.3 Japan and China: Pricing, Listing, and Negotiation Pathways
6.4 Other Priority Markets: Brazil, Canada, Australia, and Key EMs
6.5 Sequencing Launches and Coordinating Global–Local Access Plans

Chapter 7. Evidence and Value Demonstration for Market Access

7.1 Designing the Integrated Evidence Generation Plan (IEGP)
7.2 Clinical Evidence: RCTs, RWE, and Post-Marketing Commitments
7.3 Economic and Humanistic Evidence: Cost-Effectiveness, Budget Impact, PROs
7.4 Value Dossiers and Payer Communication Materials (GVD, AMCP Dossier, etc.)
7.5 Managing Evidence Gaps and Uncertainty at Launch

Chapter 8. Analyses in Support of Market Access and Reimbursement

8.1 Epidemiology and Patient Flow Analyses
8.2 Pricing and Elasticity Analyses (Price Corridor, WTP, Reference Pricing)
8.3 Cost-Effectiveness Models and Budget Impact Analyses
8.4 Access Scenario Modeling and Sensitivity Analyses
8.5 Post-Launch Performance Tracking: Uptake, Access, and Affordability Metrics

Chapter 9. Market Access Systems, Processes, and Tools

9.1 Core Processes: Access Planning, Governance, and Decision Rights
9.2 Systems Landscape: CRM, Contract Management, and Pricing Systems
9.3 Analytics and Dashboards for Access and Reimbursement Performance
9.4 Digital Tools for Payer Engagement and Field Market Access Teams
9.5 Data, Controls, and Compliance in Access Operations

Chapter 10. Data Sources and Providers for Market Access Professionals

10.1 Claims, EHR, and Registry Data: What They Are and How They’re Used
10.2 Sales, Channel, and Distribution Data (e.g., Retail and Specialty)
10.3 Pricing and Reimbursement Databases (List, Net, Discounts, and Rebates)
10.4 Patient-Level and RWE Data Providers and Partnerships
10.5 Evaluating and Selecting Data Providers for Your Use Case

Chapter 11. Organizational Models and Roles in Market Access

11.1 Typical Market Access Org Chart at a Mid-to-Large Pharma
11.2 Key Roles and Profiles: Global, Regional, and Local Access Leads
11.3 Interfaces with HEOR, Medical Affairs, Commercial, and Finance
11.4 Building and Developing Market Access Capabilities
11.5 Governance Models for Global–Local Alignment

Chapter 12. The Payor Perspective on Market Access and Reimbursement

12.1 How Payors Define Value and Manage Budget Constraints
12.2 Payor Decision-Making Processes and Committees
12.3 Contract Types: Rebates, Outcomes-Based Contracts, and Risk-Sharing
12.4 Common Payor Concerns and Objections (and How They View Manufacturer Data)
12.5 Building Trust and Long-Term Relationships with Payors

Chapter 13. Pricing, Contracting, and Innovative Access Models

13.1 Traditional Pricing Models and Discounts
13.2 Outcomes-Based and Value-Based Agreements
13.3 Access Schemes for High-Cost Therapies (e.g., Cell and Gene, Rare Disease)
13.4 Managed Entry Agreements and Conditional Reimbursement
13.5 Future Directions: Bundled Payments, Subscription Models, and Beyond

Chapter 14. Patient Access, Affordability, and Support Programs

14.1 Patient Assistance, Co-Pay Support, and Foundation Models
14.2 Navigating Accessibility: Prior Authorization, Step Edits, and Tiering
14.3 Health Equity and Access for Underserved Populations
14.4 Integrating Patient Advocacy and Insights into Access Strategy
14.5 Guardrails: Compliance, Anti-Kickback Considerations, and Transparency

Chapter 15. Market Access for Special Asset Types

15.1 Oncology and Immunology: Rapid Innovation and Complex Pathways
15.2 Rare Diseases and Ultra-Orphan Therapies
15.3 Vaccines and Preventive Therapies
15.4 Cell and Gene Therapies and One-Time Curative Treatments
15.5 Combination Therapies and Companion Diagnostics

Chapter 16. Planning and Executing a Market Access Project

16.1 Defining Objectives, Scope, and Success Metrics
16.2 Project Phases: Diagnostic, Design, Piloting, and Implementation
16.3 Stakeholder Engagement Plan: Internal and External
16.4 Checklists and Templates for Access Project Management
16.5 Common Failure Modes and How to Avoid Them

Chapter 17. Country and Region Playbooks: Templates and Checklists

17.1 Standard Country Market Access Profile Template
17.2 Launch Readiness Checklist by Country/Region
17.3 Reimbursement Dossier Preparation Checklist
17.4 In-Market Monitoring and Early Warning Indicators
17.5 Rapid Diagnostic Template for Underperforming Markets

Chapter 18. Working with External Partners and Advisors

18.1 When to Bring in External Support on Market Access
18.2 Large Consulting Firms: Offerings, Strengths, and Limitations
18.3 Specialist Market Access Agencies and HEOR Consultancies
18.4 Independent Market Access Consultants and Networks (e.g., via Umbrex)
18.5 Designing and Managing Effective External Engagements

Chapter 19. Ethics, Compliance, and Reputation in Market Access

19.1 Operating Within Legal and Regulatory Boundaries
19.2 Transparency Requirements and Reporting (e.g., Sunshine, Disclosure)
19.3 Managing Conflicts of Interest with Payors and Providers
19.4 Ethical Considerations in Pricing and Access for Patients
19.5 Embedding Compliance into Everyday Market Access Work

Chapter 20. Looking Ahead: The Future of Global Market Access

20.1 Emerging Trends: RWE, Personalized Medicine, and Digital Health
20.2 Evolution of HTA and Payor Expectations
20.3 AI, Advanced Analytics, and Automation in Market Access
20.4 Scenarios for the Next 5–10 Years in Key Markets
20.5 Building a Future-Proof Market Access Organization